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Abstract
Chronic activation of mu-opioid receptors, which couple to
pertussis toxin-sensitive Gai/o proteins to inhibit adenylyl
cyclase (AC), leads to a compensatory sensitization of AC.
Pertussis toxin-insensitive mutations of Gai/o subtypes, in
which the pertussis toxin-sensitive cysteine is mutated to
isoleucine (GaCIi=o), were used to determine whether each of







i3 were individually transiently
transfected into C6 glioma cells stably expressing the mu-
opioid receptor, or transiently co-expressed with the mu-
opioid receptor into human embryonic kidney (HEK)293T
cells. Cells were treated with pertussis toxin to uncouple
endogenous Gai/o proteins, followed by acute or chronic
treatment with the mu-opioid agonist, [D-Ala2,N-Me-Phe4,
Gly5-ol]enkephalin (DAMGO). Each Gai/o subtype mediated
acute DAMGO inhibition of AC and DAMGO-induced sensi-
tization of AC. The potency for DAMGO to stimulate sensi-
tization was independent of the Gai/o subtype, but the level of
sensitization was increased in clones expressing higher
levels of Gai/o subunits. Sensitization of AC mediated by a
component of fetal bovine serum, which was also dependent
on the level of functional Gai/o subunits in the cell, was
observed. This serum-mediated sensitization partially
masked mu-opioid-mediated sensitization when expressed
as percentage overshoot due to an apparent increase in AC
activity.
Keywords: adenylyl cyclase, cAMP overshoot, Gai/o sub-
types, mu-opioid, pertussis toxin, sensitization.
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The long-term use of mu-opioid agonists for the treatment of
pain is complicated by the development of dependence,
demonstrated by withdrawal upon removal of the agonist,
and tolerance, a reduced response with the same amount of
agonist. Although the development of dependence and
tolerance usually coincide, they have separate mechanisms
of development (Bohn et al. 2000; Yoshimura et al. 2000).
At the cellular level, dependence is indicated by a sensiti-
zation of adenylyl cyclase (AC) (Sharma et al. 1975), also
referred to as cAMP overshoot or heterologous sensitization
of AC (Watts 2002). This follows chronic Gai/o inhibition
and is measured as an increase in Gas- or forskolin-
stimulated cAMP accumulation upon removal of agonist.
The mechanisms of the development of sensitization follow-
ing chronic Gai/o-mediated inhibition are slowly being
unraveled (Watts 2002).
Of the nine AC isoforms, only ACI, ACV, ACVI and
ACVIII are strongly sensitized (Watts and Neve 1996;
Avidor-Reiss et al. 1997; Nevo et al. 1998, 2000; Rhee et al.
2000; Cumbay and Watts 2001). Enhanced Gas-AC coupling
has been proposed as a mechanism for sensitization (Watts
and Neve 1996; Vortherms et al. 2004). Evidence for the
intermediaries involved in the mediation of sensitization
includes a requirement for Gbc (Avidor-Reiss et al. 1996;
Rhee et al. 2000; Rubenzik et al. 2001), a role for Raf-1
(Varga et al. 1999, 2002, 2003), and a selective role for
protein kinase A (PKA) (Johnston et al. 2002) and protein
kinase C (PKC) (Varga et al. 2003; Beazely and Watts 2005;
Beazely et al. 2005).
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Although all of the Ga subtypes of the Gai/o family (GaoA,
GaoB, Gai1, Gai2, Gai3 and Gaz) are able to mediate acute
inhibition of AC (Gerhardt and Neubig 1991), the ability of a
single Gai/o subtype to mediate AC sensitization has only
been demonstrated for Gao (Watts et al. 1998; Clark et al.
2004), Gai2 (Nakagawa et al. 1999), and Gaz with ACV but
not ACVI (Ammer and Christ 2002). In other studies, Gai1,
Gai2 or Gai3 have not been able to mediate sensitization alone
(Watts et al. 1998; Tso andWong 2000; Tso and Wong 2001),
leading to the suggestion that multiple Ga subtypes are
required for opioid-induced sensitization (Tso and Wong
2000). This is supported by a decreased level of sensitization
in cells expressing only one functional Ga subtype compared
with wild-type cells expressing multiple Ga subtypes (Watts
et al. 1998; Nakagawa et al. 1999; Clark et al. 2004).
Therefore, it can be predicted that the different Gai/o subtypes
have different efficiencies in mediating sensitization, which
may not correlate with efficiencies for acute inhibition of AC
and could be AC isoform dependent. There is evidence for a
subtype selective effect on acute inhibition of AC. For
example, dopamine D2S receptor-mediated inhibition of
forskolin-stimulated AC is mediated by Gai2 and not Gai3,
but prostaglaudin E1-stimulated AC is mediated by Gai3 and
not Gai2 in murine Ltk- cells that contain ACI, ACVI and
other isoforms (Ghahremani et al. 1999); a2-adrenergic
inhibition of PKC-stimulated ACII in Sf9 cells can be
mediated by Gao but not Gai1 (Näsman et al. 2002).
The aim of this study was to determine whether Gai1 and
Gai3, like Gai2 and GaoA, are able to mediate sensitization,
and to investigate factors which may influence the degree of
sensitization, including Ga expression levels and the degree
of acute AC inhibition. For this purpose, Ga subunits with an
Ile replacement of the pertussis toxin (PTX)-sensitive Cys







expressed in C6 glioma cells stably expressing the mu-opioid
receptor (C6l), or transiently co-expressed in HEK293T cells
with the mu-opioid receptor. Cells were treated with PTX to
inactivate endogenous G proteins before acute or chronic
treatment with mu-opioid agonist. Sensitization following
agonist treatment was determined by measuring forskolin-
stimulated cAMP accumulation in the presence of naloxone,
an opioid antagonist. The results demonstrated that GaoA,
Gai1, Gai2 and Gai3 are each able to mediate mu-opioid




Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum
(FBS), trypsin-EDTA, LipofectAMINE Plus Reagent, Geneticin and
Zeocin were purchased from Invitrogen (Carlsbad, CA, USA).
Pertussis toxin (PTX) was purchased from List Biological Labor-
atories Inc. (Campbell, CA, USA). [D-Ala2, N-Me-Phe4,Gly5-
ol]enkephalin (DAMGO), guanosine 5¢-diphosphate (GDP),
3-isobutyl-1-methylxanthine (IBMX), forskolin, Trizma base and
other chemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Human PTX-insensitive GaCIo=i pDNA (with a cysteine
to isoleucine mutation at the PTX-sensitive cysteine near the
C-terminus) was purchased from UMA cDNA Resource Center
(http://www.cDNA.org). Rat PTX-insensitive GaCGo=i and mouse
PTX-insensitive GaCGoA pDNA were obtained from Steve Ikeda
(Guthrie Research Institute, Sayre, PA, USA). QIAGEN Plasmid
Maxi Kits were purchased from QIAGEN, Inc. (Valencia, CA, USA).
Cell culture and expression of PTX-insensitive Ga
C6l and HEK293T cells were grown in DMEM with 10% FBS
under 5% CO2. Geneticin (0.25 mg/mL) was included with the C6l
cells to maintain expression of the mu-opioid receptor (Clark et al.
2003). Human PTX-insensitive GaCIo=i, rat PTX-insensitive Ga
CG
i or
mouse PTX-insensitive GaCGoA DNAwas inserted into pcDNA3.1zeo
vector (Zeocin-resistant). Stable transfection of the PTX-insensitive
Gao/i constructs into C6l cells was accomplished using LipofectA-
MINE Plus Reagent, and selected using 0.4 mg/mL Zeocin, as
described previously (Clark et al. 2003). PTX-insensitive Gao/i was
transiently transfected (4 lg/10 mL plate) in C6l cells using
LipofectAMINE Plus Reagent. HEK293T cells were transiently
transfected with mu-opioid receptor (Lee et al. 1999), with or
without co-transfection with PTX-insensitive Gao/i (3 lg plus 3 lg/
10 mL plate).
Western blots
C6l cell membrane homogenates were prepared as previously
described (Clark et al. 2003) and separated (20 lg protein) by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) on a 12% gel (Protogel, National Diagnostics, Inc., Atlanta,
GA, USA). Proteins were transferred to a nitrocellulose membrane
(45 lm; Osmonics, Inc., Minnetonka, MN, USA) and probed with
1 : 6000 anti-Gai2 (Calbiochem, San Diego, CA, USA) in 5% non-
fat dry milk or 1 : 200 anti-Gao (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) in 5% non-fat dry milk. Bands were visualized
using horseradish peroxidase-conjugated goat anti-rabbit IgG in 5%
non-fat dry milk, followed by enhanced chemiluminescence (West
Pico Super Signal, Pierce, Rockford, IL, USA) and quantification
using an Eastman Kodak Image Station 440 (Eastman Kodak,
Rochester, NY, USA).
cAMP accumulation assay
C6l cells expressing endogenous Ga proteins, or stably expressing
PTX-insensitive Gao/i proteins, were plated to 80–90% confluency
in 24-well plates with DMEM plus 10% FBS and immediately
treated with 100 ng/mL PTX. Transiently transfected cells
(HEK293T and C6l) were plated into 24-well plates with DMEM
and 10% FBS 24 h after transfection, and immediately treated with
100 ng/mL PTX. After 6 h, varying concentrations of DAMGO
were added, without removing the PTX, and 18 h later cells were
assayed for forskolin-stimulated cAMP accumulation. Cell media
were replaced with serum-free DMEM containing 5 lM forskolin,
1 mM IBMX and 10 lM naloxone (for sensitization), or 0–10 lM
DAMGO (for acute inhibition), and allowed to incubate for 10 min
at 37C. The reaction was stopped by replacing the media with ice-
cold 3% perchloric acid. Accumulated cAMP was measured using a
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[3H]cAMP liquid phase assay kit (Diagnostic Products Corp., Los
Angeles, CA, USA) as previously described (Clark et al. 2003).
Sensitization (overshoot) was determined as the percentage increase
or as the increase in picomoles of cAMP per microgram of protein in
forskolin-stimulated cAMP accumulation, over that in the absence
of an 18 h DAMGO pre-treatment. Acute inhibition was determined
as the percentage decrease in forskolin-stimulated cAMP accumu-
lation compared with that in the absence of opioid agonist.
Data analysis
Data from each experiment were fitted to sigmoidal concentration-
response curves, using GRAPHPAD PRISM (San Diego, CA, USA), for
calculation of mean maxima and EC50 values ± SEM from at least
three separate experiments. For studies on transiently transfected
cells, results are means ± SEM from at least three separate
transfections. Values were compared using one-way ANOVA with
Tukey’s post hoc test or, when appropriate, by two-way ANOVA.
Figure representations of the data are presented as means ± SEM
from at least three separate experiments.
Results
PTX-insensitive Gai/o subunits rescue DAMGO-mediated
sensitization of AC in PTX treated cells
Forskolin at a concentration of 5 lM strongly activates AC in
C6l cells and allows observation of a robust overshoot of
cAMP accumulation following chronic mu-opioid treatment
(Clark et al. 2004). DAMGO caused a strong inhibition
(81 ± 6%) of 5 lM forskolin-stimulated AC, with an EC50
value of 17 ± 9 nM, in C6l cells expressing endogenous Ga
subtypes (Fig. 1a). Treatment of C6l cells for 18 h with
DAMGO, followed by removal of agonist and addition of the
opioid antagonist, naloxone, resulted in an increase in
forskolin-stimulated cAMP accumulation of 226%, equival-
ent to an increase of 5.2 ± 0.5 pmol cAMP/lg protein
(Fig. 1b). A similar percentage increase (206%) was seen
when overshoot was measured in the absence of forskolin,
although this only represented 0.11 pmol cAMP/mg protein
or 2.1% of the forskolin-stimulated increase (see legend to
Fig. 1). The EC50 for DAMGO to induce this sensitization
was 6.8 ± 1.2 nM (Fig. 1b). Treatment of cells with 100 ng/
mL PTX for 24 h before DAMGO completely eliminated
both DAMGO-mediated acute inhibition and sensitization
(Fig. 1), in agreement with our findings that this level of
PTX uncouples endogenous Gai/o proteins in these cells
(Clark et al. 2006). Similarly, in HEK293T cells transiently
transfected with the mu-opioid receptor, acute inhibition of
forskolin-stimulated AC by DAMGO (50 ± 11%) was
completely eliminated by treatment with 100 ng/mL PTX
for 24 h (1 ± 3%), and sensitization following overnight
treatment with DAMGO (14 ± 1%), although small in those
cells transiently transfected with mu-opioid receptor alone,
was also completely eliminated by PTX treatment.
Transient transfection with individual PTX-insensitive
Cys-Ile mutant Ga subtypes (GaCI) rescued both acute
inhibition of forskolin-stimulated cAMP accumulation by
DAMGO and DAMGO-mediated sensitization following
PTX treatment in C6l cells (Fig. 2a). In HEK293T cells
transiently co-transfected with the mu-opioid receptor
together with the PTX-insensitive Gai/o subunit proteins,
GaCI subtypes rescued both acute inhibition of forskolin-
stimulated cAMP accumulation by DAMGO and DAMGO-
mediated sensitization following PTX treatment (Fig. 2b).
Fig. 1 Effects of acute and chronic DAMGO on forskolin-stimulated
cAMP accumulation in C6l cells. C6l cells expressing endogenous
Ga proteins were plated into 24-well plates and treated with or without
PTX 24 h before the assay. (a) Acute inhibition by DAMGO. (b)
Overshoot following an 18 h treatment with 0–10 lM DAMGO. To start
the cAMP assay, medium was replaced with DMEM without FBS and
containing 5 lM forskolin, 1 mM IBMX and 0–10 lM DAMGO (a), or
10 lM naloxone (b). After 10 min at 37C, the assay was stopped and
cAMP levels were measured as described in Materials and methods.
Data are presented as percentage of control (without DAMGO) values.
Shown are the combined data ± SEM from three experiments, each
performed in duplicate. Forskolin-stimulated cAMP levels in DAMGO-
naı̈ve cells are given in Table 3. Maximum cAMP overshoot was
226 ± 21% and equivalent to an increase of 5.2 ± 0.5 pmol cAMP/lg
protein (Table 2). Basal (in absence of forskolin stimulation) levels of
cAMP accumulation in control and chronic DAMGO-treated C6l cells
were 0.054 ± 0.027 and 0.165 ± 0.031 pmol cAMP/lg protein,
respectively (n ¼ 3), representing an overshoot of 206%.
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The ratio of the degree to which sensitization was rescued
compared with the degree to which inhibition was rescued
was similar for each GaCI subtype (for HEK293T cells, this
ranged from 1.6 ± 0.2 for Gai3 to 2.3 ± 0.4 for Gai2; for C6l
cells, the range was 1.1 ± 0.3 for GaoA to 1.8 ± 0.5 for
Gai1).
The PTX-insensitive mutant of Gai1 in which the Cys at
residue 351 is replaced by Ile is very efficient at coupling to
receptor compared with Cys itself, or compared with
replacement of this Cys with Ser or Gly, when activated by
a2A-adrenergic agonists (Bahia et al. 1998). Similarly, the
Cys-Ile mutant is activated by mu-opioid agonists at least six
times more efficiently than the Cys-Gly mutant, as measured
by stimulation of [35S]GTPcS binding, for each of the Ga
subtypes used in this study (data not shown). With the very
efficiently coupled GaCI. Subtypes, there is a concern that
selectivity of coupling could be lost. To address this, stable
clones of C6l cells expressing the less efficiently coupled
Cys-Gly mutant Ga subtypes (GaCG) were tested. DAMGO-
mediated overshoot was rescued in PTX-treated cells, with
GaCGi1 (18 ± 11%, EC50 ¼ 180 ± 60 nM), GaCGi2 (26 ± 10%,
EC50 ¼ 22 ± 18 nM) and GaCGoA (31 ± 8%, EC50 ¼ 55 ±
33 nM; Clark et al. 2004). Maximal acute inhibition by
DAMGO was 44 ± 5% in PTX-treated GaCGi2 cells and 29 ±
3% in PTX-treated GaCGi1 cells.
DAMGO-mediated sensitization of AC is dependent on




The degree of DAMGO-mediated inhibition or sensitization
of AC was similar with transient transfection of each of the
PTX-insensitive GaCI subtypes, but less than that seen in
cells expressing only endogenous Gao/i proteins. Conse-
quently, it would appear that Ga expression level may be
more important than Ga subtype in determining the degree of
inhibition or sensitization of AC. If so, a single Ga subtype
should be able to restore inhibition and sensitization levels to
those seen in non-PTX-treated C6l cells expressing only
endogenous Ga proteins, without a need for the involvement
of multiple Ga subtypes.
To test this, clones of C6l cells stably expressing high or
low levels of PTX-insensitive GaoA or Gai2, as determined
by western blot (Fig. 3), were prepared. As with their
transiently transfected counterparts, there was rescue of
PTX-sensitive AC inhibition and sensitization. Following
PTX treatment, clones expressing the higher levels of PTX-
insensitive Gao/i had increased percentage inhibition of
forskolin-stimulated cAMP accumulation by DAMGO,
comparable with the levels seen in untreated C6l cells
expressing only endogenous Ga proteins, with no significant
change in DAMGO potency (Table 1). In contrast, there was
(a)
(b)
Fig. 2 Rescue of DAMGO-mediated inhibition and sensitization of
adenylyl cyclase by PTX-insensitive GaCIi=o in PTX-treated cells. (a)
C6l cells transiently transfected with PTX-insensitive GaCIi=o or (b)
HEK293T cells co-transfected with mu-opioid receptor and PTX-
insensitive GaCIi=o were treated with 100 ng/mL PTX for 24 h. The mu-
opioid inhibition (filled bars) of forskolin (5 lM)-stimulated cAMP
accumulation was measured with 10 lM DAMGO. Overshoot (open
bars) of forskolin-stimulated cAMP accumulation was measured with
10 lM naloxone following an 18 h treatment with 1 lM DAMGO. Data
are presented as percentage of control (without DAMGO). Details are
given in Materials and methods. Shown are the combined data from
three separate experiments, each performed in duplicate; *p < 0.05 or
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Fig. 3 Western blots of GaCIoA or Ga
CI
i2 stably expressed in C6l cells.
Membrane proteins (20 lg) from C6l cells stably expressing (a) GaCIoA
or (b) GaCIi2 were separated by SDS–PAGE, transferred to a nitrocel-
lulose membrane and probed with anti-Gao or anti-Gai2, as described
in Materials and methods. His6-Gao (Dr R. Neubig) and Gai2 (Santa
Cruz Biotechnology) were used as standards. Shown is a represen-
tative blot from three experiments.
Gai/o subtypes and adenylyl cyclase sensitization 1497
 2006 The Authors
Journal Compilation  2006 International Society for Neurochemistry, J. Neurochem. (2006) 99, 1494–1504
no difference between the high and low expressing GaoCI
cells, and only a twofold difference between the GaCIi2 in the
percentage overshoot of cAMP induced by chronic DAMGO
treatment (Figs 4a and c). Surprisingly, if overshoot was
expressed as the difference in picomoles of cAMP per
microgram of protein between DAMGO-treated and
-untreated cells, there was a 4-fold or 11-fold increase in
cells expressing the higher levels of PTX-insensitive GaCIoA or
GaCIi2 , respectively, with no change in the potency of
DAMGO (Figs 4b and d). This discrepancy would appear
to be due to different levels of forskolin-stimulated cAMP
accumulation in the DAMGO-naı̈ve cells (Figs 4b and d) and
is addressed below. The levels of sensitization in the PTX-
treated GaCIoA- or Ga
CI
i2 -expressing cells were lower than those
seen in C6l cells expressing endogenous Ga proteins,
measured as percentage increase or picomoles per microgram
of protein (Fig. 4).
Combined effects of exogenous PTX-insensitive Ga and
endogenous Ga for mu-opioid-mediated sensitization or
inhibition of forskolin-stimulated cAMP accumulation
One reason for incomplete recovery of sensitization by
expression of GaCIoA or Ga
CI
i2 to levels seen in C6l cells
expressing only endogenous Ga proteins could be compe-
tition between the exogenous mutated Gai/o proteins and
endogenous Gai/o proteins. To determine whether the effects
of the exogenously-expressed PTX-insensitive Ga subunits
were additive or competitive with the endogenously-
expressed Ga, inhibition and sensitization of cAMP accu-
mulation were examined without PTX treatment. DAMGO
inhibition of forskolin-stimulated cAMP accumulation in
GaCIoA- or Ga
CI
i2 -expressing C6l cells was not significantly
different from that in the wild-type cells (p ¼ 0.13), although
the higher expressing clones tended to have greater inhibition
(Table 2). There was no difference between any of the clones
in the potency of DAMGO to inhibit forskolin-stimulated
AC. DAMGO-mediated sensitization in the GaCIoA- or Ga
CI
i2 -
expressing cells was also similar to that of cells expressing
endogenous Ga proteins (Table 2), with no change in
potency. Sensitization in the absence of PTX treatment was
not significantly different than that in C6l cells expressing
endogenous Ga proteins in any of the clones, except low
GaCIoA, but only if expressed as percentage overshoot rather
Table 1 Maximal inhibition of forskolin-stimulated cAMP accumulation
by DAMGO is dependent on the expression levels of PTX-insensitive






Low GaCIoA 45 ± 3%*** 27 ± 14 nM
High GaCIoA 92 ± 4% 14 ± 4 nM
Low GaCIi2 43 ± 3%*** 57 ± 18 nM
High GaCIi2 83 ± 2% 8 ± 2 nM
Endogenous Ga ) PTX 81 ± 6% 17 ± 9 nM
Endogenous Ga + PTX 3 ± 2%*** –
cAMP accumulation in the presence of 5 lM forskolin and 0–10 lM
DAMGO was measured in C6l cells expressing endogenous Ga
proteins or in PTX-treated C6l cells stably transfected with PTX-
insensitive GaCI as described in Materials and methods. Maximal
inhibition and EC50 values were derived from concentration–response
curves. Shown are the means ± SEM from three separate experi-
ments, each performed in duplicate. ***p < 0.001, compared with cells
expressing only endogenous Gaproteins not treated with PTX.
Forskolin-stimulated cAMP levels in the absence of DAMGO treatment





Fig. 4 DAMGO-induced cAMP overshoot
in C6l cells expressing different amounts of
PTX-insensitive Gao or Gai2. C6l cells
expressing low or high levels of GaCIoA or
GaCIi2 (Fig. 3), or only endogenous Ga pro-
teins (C6l), were plated into 24-well plates
then treated with PTX for 24 h followed by
0–10 lM DAMGO for 18 h. To start the
assay, media were replaced with DMEM
without FBS and containing 5 lM forskolin,
1 mM IBMX and 10 lM naloxone. After
10 min at 37C, the assay was stopped
and cAMP levels were measured as
described in Materials and methods. Data
are presented as percentage of control
(non-DAMGO-treated cells) (a and c) or as
pmol cAMP/lg protein (b and d). Shown are
the combined data ± SEM from three
experiments, each performed in duplicate.
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than the increase in picomoles of cAMP per microgram of
protein, again due to differences in forskolin-stimulated
cAMP accumulation in untreated cells (Table 3). These
results demonstrate that the exogenously-expressed, PTX-
insensitive Ga subunits and the endogenous Ga do not
interfere with each other functionally.
Forskolin-stimulated cAMP accumulation is dependent
on the level of functional Ga
The discrepancy in changes in sensitization with Ga
expression between percentage over untreated values and
values expressed as an increase in picomoles of cAMP per
microgram of protein (Fig. 4) can be explained by a
difference in the degree of forskolin-stimulated cAMP
accumulation in the absence of DAMGO treatment. In
PTX-treated cells expressing higher levels of GaCIoA or Ga
CI
i2 ,
forskolin-stimulated cAMP accumulation was significantly
greater than in cells expressing lower levels of the Ga
proteins, or in PTX-treated wild-type cells. In the absence of
PTX treatment, forskolin-stimulated cAMP accumulation
was higher than in the PTX-treated cells in each of the clones
tested (Table 3). This was significant for each of the clones,
except high GaCIoA. These findings indicate that increasing
levels of functional Gai/o increased forskolin-stimulated
cAMP accumulation. This was unexpected because intui-
tively, increased expression of inhibitory Ga subunits should
decrease forskolin-stimulated cAMP accumulation. A poss-
ible explanation for these results is that there is a tonic level
of sensitization, independent of the DAMGO-mediated
sensitization, which is exposed during the assay. This most
likely occurs with the replacement of the maintenance
medium, containing FBS, with medium without FBS to start
the cAMP accumulation assay. Therefore, the sensitizing
agonist would be a component of FBS or a compound that is
released by the cells.
To determine whether a component of FBS does indeed
cause sensitization, forskolin-stimulated cAMP accumulation
was measured in C6l cells, expressing only endogenous Ga
proteins, immediately after removal of FBS. In these cells,
there was a large increase (0.95 pmol/lg protein equivalent
to an overshoot of 100%) in the level of forskolin-stimulated
cAMP accumulation compared with cells maintained in the
presence of FBS, indicating a sensitization of AC by the FBS
(Fig. 5a). However, when forskolin-stimulated cAMP accu-
mulation was measured after the cells had been treated with
serum-free FBS for 30 min, the increase in forskolin-
stimulated cAMP accumulation was no longer evident. This
increased level of forskolin-stimulated cAMP accumulation
immediately following removal of FBS was also seen in cells
Table 2 DAMGO-mediated inhibition and
overshoot of forskolin-stimulated cAMP
accumulation without PTX treatment in C6l










Low GaCIoA ) PTX 84 ± 2 9 ± 1 6.5 ± 0.9 365 ± 46* 12 ± 3
High GaCIoA ) PTX 99 ± 1 15 ± 3 4.7 ± 1.0 160 ± 14 5 ± 1
Low GaCIi2 ) PTX 89 ± 2 18 ± 6 5.3 ± 1.0 169 ± 11 7 ± 1
High GaCIi2 ) PTX 97 ± 1 20 ± 1 5.6 ± 0.5 173 ± 35 8 ± 2
Endogenous Ga ) PTX 81 ± 6 17 ± 9 5.2 ± 0.5 226 ± 21 7 ± 1
In the absence of PTX treatment, inhibition and overshoot of 5 lM forskolin-stimulated cAMP
accumulation by DAMGO (0–10 lM) was measured in C6l cells stably expressing PTX-insensitive
GaCI or in C6l cells only expressing endogenous Ga proteins as described in Materials and
methods. Maximal responses and EC50 values were derived from dose–response curves. Shown
are the means ± SEM from three separate experiments, each performed in duplicate; *p < 0.05
compared with C6l cells expressing only endogenous Ga proteins in the absence of PTX treat-
ment. Forskolin-stimulated cAMP levels in non-DAMGO treated cells are given in Table 3.
Table 3 Forskolin-stimulated cAMP accumulation is dependent on the





+ PTX – PTX
Low GaCIoA 0.8 ± 0.1 1.8 ± 0.1
#
High GaCIoA 3.7 ± 0.3* 4.2 ± 0.5
Low GaCIi2 0.9 ± 0.1 3.0 ± 0.9
#
High GaCIi2 2.2 ± 0.3* 4.2 ± 0.7
#
Endogenous Gaa 0.8 ± 0.2 2.4 ± 0.2#
Forskolin (5 lM)-stimulated cAMP accumulation in C6l cells stably
expressing PTX-insensitive GaCI or C6l cells expressing only
endogenous Ga proteins with or without PTX treatment as described
in Materials and methods. Shown are the means ± SEM from at least
three separate experiments, each performed in duplicate; *p < 0.05
compared with C6l cells expressing only endogenous Ga proteins
with PTX treatment; #p < 0.05 compared with same clone with PTX
treatment. aBasal values in the absence of forskolin were
0.022 ± 0.004 pmol/lg protein in the presence of PTX treatment and
0.027 ± 0.01 pmol/lg protein in the absence of PTX treatment.
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expressing PTX-insensitive Gai2, with or without PTX
treatment (Fig. 5b). There was also an increase in endog-
enous cAMP levels in C6l cells (in the absence of forskolin)
on removal of FBS, although in absolute terms this was very
small compared with the overshoot in the presence of
forskolin. Thus, C6l cells in the presence of FBS contained a
basal level of 0.012 ± 0.003 pmol/cAMP/lg protein, which
was increased to 0.027 ± 0.011 pmol cAMP/lg protein
when assayed immediately after removal of the FBS,
representing an overshoot of 125%. This effect was lost on
PTX treatment of the cells (with FBS ¼ 0.022 ± 0.005 pmol
cAMP/lg protein; without FBS ¼ 0.022 ± 0.004 pmol
cAMP/lg protein). Addition of naloxone in the presence of
FBS had no effect on forskolin-stimulated cAMP accumu-
lation levels in any of the clones tested (data not shown),
indicating that if tonic sensitization was caused by a
component of FBS this did not involve the mu-opioid
receptor.
Forskolin-stimulated cAMP accumulation following
DAMGO treatment was measured in the continued presence
of FBS to examine whether a larger DAMGO-mediated
overshoot could be revealed by eliminating the FBS-
mediated overshoot. The level of DAMGO-mediated over-
shoot was increased significantly in the presence of FBS in
cells expressing endogenous Ga proteins, or heterologously
expressing Gai2 proteins, if measured as percentage over-
shoot (Fig. 6a). In contrast, cAMP overshoot was increased
Fig. 5 Effect of removal of FBS on forskolin-stimulated cAMP in naı̈ve
C6l cells. Cell media (DMEM with 10% FBS) were replaced with
serum-free DMEM for varying times, before (a) or simultaneously with
(b) stimulation of cAMP with forskolin, in C6l cells expressing
endogenous Ga proteins (a and b) and stably expressing PTX-
insensitive Gai2, with or without PTX-treatment (b). Accumulated
cAMP was determined 10 min after addition of 5 lM forskolin and
1 mM IBMX, as described in Materials and methods. Shown are the
combined data from three separate experiments, each performed in
duplicate. In (a) the value at time zero and dashed line represent the
level of forskolin-stimulated cAMP production when serum was not
removed from the media; **p < 0.005, *p < 0.05 vs. with FBS.
(a)
(b)
Fig. 6 Effect of FBS on cAMP overshoot in chronic DAMGO-treated
C6l cells. Cells expressing only endogenous Ga proteins or PTX-
insensitive Gai2 proteins (higher expressing cells shown in Fig. 3)
were grown in DMEM with 10% FBS, then treated for 24 h with or
without PTX followed by 18 h in the presence of 1 lM DAMGO. Media
were then replaced with DMEM in the presence or absence of 10%
FBS and 10 lM naloxone to induce overshoot. cAMP levels were as-
sayed after addition of 5 lM forskolin and 1 mM IBMX as described in
Materials and methods. Data are expressed as percentage increase
in cAMP in DAMGO-treated cells over untreated cells (a), or as the
increase in pmol cAMP/lg protein over untreated cells (b). Shown are
the mean ± SEM from three separate experiments, each performed in
duplicate. The levels of forskolin-stimulated cAMP in naı̈ve cells (pmol/
lg protein) are shown in Fig. 5(b); ***p < 0.001, **p < 0.005, *p < 0.05
compared with absence of FBS. There are no significant differences
between the presence and absence of FBS in D pmol cAMP/lg protein
(b).
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only slightly (and not significantly) in the presence of FBS
when measured as change in picomoles of cAMP per
microgram of protein, and did not reach significance
(Fig. 6b), showing that the AC sensitization by DAMGO is
not inherently altered by FBS, or that there is a ceiling to the
degree of sensitization that can be achieved. Maximal acute
inhibition of AC by 1 lM DAMGO was not significantly
affected by the presence of FBS. In C6l cells, this was
89 ± 2% and in high expressing GaCIi2 cells, it was 94 ± 1%
or, after PTX-treatment, 78 ± 2%.
Discussion
PTX-insensitive mutations of the inhibitory Ga subtypes
were expressed in C6 glioma cells stably expressing the mu-
opioid receptor to determine whether GaoA, Gai1, Gai2 and
Gai3 are all able to rescue the chronic mu-opioid-mediated
sensitization of adenylyl cyclase (AC) lost on treatment with
PTX. Although we cannot directly compare expression levels
of the different Ga CI subtypes based on the ratio between the
level of rescue of sensitization and inhibition of AC, there
would appear to be no significant differences between the
GaCI subtypes in mediating inhibition or sensitization of AC
in either C6l or HEK293 cells.
Results from previous studies that examined the abilities
of PTX-insensitive Ga proteins to rescue sensitization of AC
have been conflicting (Table 4). One explanation for some of
these divergent findings could be that different AC isoforms
are expressed in the various cell lines, and that there is Ga
selectivity for mediation of sensitization. Indeed, Gaz is able
to mediate sensitization with overexpression of ACV, but not
ACVI, in COS-7 or HEK293 cells expressing the mu-opioid
receptor (Ammer and Christ 2002). C6 cells predominately
express ACVI (Debernardi et al. 1993). However, differen-
tial AC isoform requirements do not explain the discrepancy
between our findings with GaCI mutants in HEK293 cells
and those of Tso and Wong (2000) with the GaCG mutants in
the same cell type. These conflicting results may be
explained by the use of different PTX-insensitive mutations
that are quantitatively differently activated by agonist-
Table 4 Abilities of PTX-insensitive Ga
subunits to rescue adenylyl cyclase sensi-
tization following PTX treatment
PTX-insensitive Ga
protein and mutation Receptor Cell type Rescue Reference
Gao
CI mu C6 Yes This paper
CG mu C6 Yes Clark et al. (2004)
CG D2L NS20Y Yes Watts et al. (1998)
Gai1
CI mu C6 Yes This paper
CI mu HEK293 Yes This paper
CG D2L NS20Y No Watts et al. (1998)
kappa HEK293 No Tso and Wong (2001)
mu HEK293 No Tso and Wong (2001)
delta HEK293 Yes Tso and Wong (2001)
Gai2
CI mu C6 Yes This paper
CI mu HEK293 Yes This paper
CG D2L NS20Y No Watts et al. (1998)
Gai2/Gaz chimera mu HEK293 No Tso and Wong (2000)
delta HEK293 No Tso and Wong (2000)
kappa HEK293 No Tso and Wong (2000)
Gai2/Gq chimera kappa CHO Yes Nakagawa et al. (1999)
Gai3
CI mu C6 Yes This paper
CI mu HEK293 Yes This paper
CG mu HEK293 No Tso and Wong (2001)
kappa HEK293 No Tso and Wong (2001)
D2L NS20Y No Watts et al. (1998)
Gai2 + Gai3
Wild-type mu with ACVI COS-7 Yes Ammer and Christ (2002)
mu with ACV COS-7 Yes Ammer and Christ (2002)
Gaz
Wild-type mu with ACV COS-7 HEK293 Yes Ammer and Christ (2002)
Wild-type mu with ACVI COS-7 HEK293 No Ammer and Christ (2002)
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occupied receptor. The Cys-Ile PTX-insensitive mutant is at
least six times more efficiently activated than the Cys-Gly
mutant in DAMGO-mediated stimulation of [35S]GTPcS
binding for each of the subtypes, and in a2A-adrenoceptor-
mediated stimulation of [35S]GTPcS binding with Gai1
(Bahia et al. 1998). Although it is possible that the high
efficiency of the Cys-Ile mutation has masked any selectivity
there may be in the ability of the Gai/o subtypes to mediate
sensitization of AC in both the stable and transiently
transfected cells, we have been able to measure low levels
of DAMGO-mediated sensitization with stably expressed
GaCGi1 or Ga
CG
i2 (this study), or Ga
CG
oA (Clark et al. 2004), to
confirm that this is not the case.
The mu-opioid sensitization of AC was routinely meas-
ured as the forskolin-stimulated activity due to the low basal
levels of cAMP. Sensitization was seen in the absence of
forskolin, but this represented no more then 2% of the level
seen in the presence of forskolin. Sensitization expressed as
the difference in picomoles of cAMP per microgram of
protein between control and DAMGO-treated cells was
greater with increased expression levels of GaCIoA or Ga
CI
i2 .
Higher levels of mu-opioid receptor also increase sensitiza-
tion levels (Moulédous et al. 2005). Maximal levels of
sensitization were not significantly increased with the
combination of endogenous and exogenous Ga as measured
in the absence of PTX treatment compared with sensitization
with endogenous Ga alone. This suggests that sensitization
in the C6l cells expressing only endogenous Ga proteins
was near the maximum possible effect under those particular
assay conditions. Similarly, maximal acute DAMGO-medi-
ated inhibition of forskolin-stimulated cAMP accumulation
with the combination of endogenous and exogenous Ga as
measured in the absence of PTX treatment tended to be
higher than with endogenous Ga alone, but because this was
close to the maximum possible effect, the increase was not
statistically significant. Together, these data demonstrate that
there was no competition between the exogenous and
endogenous Ga. In further support of this lack of compe-
tition, the expression level of GaCIoA or Ga
CI
i2 had no
significant effect on the potency of DAMGO to inhibit AC
or to mediate sensitization in non-PTX-treated cells.
Surprisingly, maximal DAMGO-mediated sensitization
expressed as percentage cAMP overshoot did not reflect
maximal sensitization expressed as the increase in picomoles
of cAMP per microgram of protein. The cause of this
discrepancy proved to be a difference in the level of
forskolin-stimulated cAMP accumulation in the naı̈ve cells,
which therefore altered the derived percentage values but not
the absolute picomoles of cAMP per microgram of protein
values. The forskolin-stimulated cAMP accumulation levels
in naı̈ve cells were consistently higher in the high-expressing
clones and also higher in the absence of PTX treatment,
indicating a positive correlation with the level of functional
Gai/o. It might have been predicted that an increased level of
inhibitory Gai/o proteins would reduce forskolin-stimulated
cAMP accumulation, similar to the decrease in isoprenaline-
or GTP-stimulated adenylyl cyclase activity in membranes
from cardiac myocytes overexpressing Gai2 (Rau et al.
2003). Our results can be explained by an increase in AC
sensitization with increased levels of functional Gai/o, caused
by chronic activation of the inhibitory Ga. An overshoot was
revealed, even in the absence of DAMGO, by removal of
FBS, suggesting activation of an endogenous Gai/o-coupled
receptor by a component of FBS. Preventing this serum-
mediated overshoot by retaining FBS in the medium during
the assay decreased forskolin-stimulated cAMP accumula-
tion and revealed a large increase in the percentage
DAMGO-mediated overshoot. However, sensitization ex-
pressed as picomoles of cAMP per microgram of protein was
not significantly higher with FBS in the assay than without,
indicating that the intrinsic sensitization due to DAMGO was
not altered. Alternatively there could be a ceiling effect in the
level of cAMP overshoot in these cells.
FBS contains several components that could potentially
activate Gai/o-coupled cell-surface receptors to induce sen-
sitization of AC. Gai/o-coupled receptors expressed in C6
cells are known to include P2Y12 purinergic receptors
(Valeins et al. 1992), metabotropic glutamate receptors
(Albasanz et al. 1997), cannabinoid receptors (Sánchez
et al. 2001), 5-hydroxytryptamine 2A receptors (Elliott et al.
1995) and lysophosphatidic acid A1 receptors (Cechin et al.
2005). In addition, FBS contains growth factors, and C6 cells
express receptors for fibroblast growth factor (FGF), insulin-
like growth factor (IGF-1) and platelet-derived growth factor
(PDGF), in addition to vascular endothelial growth factor
receptors; they also secrete these growth factors (Okumura
et al. 1989; Chernausek 1993; Hamel and Westphal 2000).
Growth factors could activate receptor tyrosine kinases
(RTKs) to affect signaling and therefore, sensitization, via
mu-opioid receptor activation. Mu-opioid receptor-mediated,
extracellular signal-regulated kinase (ERK) phosphorylation
was seen to be partially dependent on epidermal growth
factor (EGF) receptor transactivation in HEK293 cells (Della
Rocca et al. 1997; Belcheva et al. 2001), and in C6 cells,
mu-opioid agonist-stimulated ERK phosphorylation was
partially reversed by inhibition of FGF receptor tyrosine
phosphorylation (Belcheva et al. 2002). The mu-opioid
receptor–RTK interactions, and their convergence in the
ERK pathway, may be particularly important for sensitization
of AC. Thus, mu- and delta-opioid-mediated sensitization of
AC in Chinese hamster ovary (CHO) cells is reduced by
inhibition of Raf-1, an intermediate in the ERK signaling
pathway (Varga et al. 2002; Yue et al. 2006). The delta-
opioid-mediated sensitization has been shown to be sensitive
to inhibition of both RTKs and PKC (Varga et al. 2003), and
both PKC and EGF enhance ACVI activity in a Raf-1-
dependent manner (Beazely et al. 2005). In support of this,
RTK activation by IGF-1 stimulated phosphorylation of
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ACVI, and this was reduced by an inhibitor of Raf-1 kinase
(Tan et al. 2001).
In summary, the effect of FBS on mu-opioid-mediated
sensitization demonstrates that the overall level of sensitiza-
tion of AC can be determined by the combined effects of
multiple receptors, possibly by a convergence of separate
pathways. FBS- and mu-opioid-mediated sensitization of AC
were both affected by the expression level of functional Gai/o,





GaCIi3 was able to mediate mu-agonist-mediated sensitization.
Together, these results suggest that receptor and G protein
stoichiometry may be more important than Ga subtype in
determining the parameters of acute and chronic effects of
mu-opioids on adenylyl cyclase.
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